ascorbic acid deficiency: A condition due to a dietary deficiency of ascorbic acid (vitamin C), characterized by malaise, lethargy, and weakness. As the disease progresses, joints, muscles, and subcutaneous tissues may become the sites of hemorrhage. Ascorbic acid deficiency frequently develops into scurvy in young children fed unsupplemented cow's milk exclusively during their first year. It develops also commonly in chronic alcoholism. (Cecil Textbook of Medicine, 19th ed, p1177)
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
170 |
4. Check minimum number of eventsNone |
170 |
5. Include endpointsNone |
170 |
6. Filter based on genotype QC (FinnGen only) |
163 |
Control definitions (FinnGen only)
- Control exclude
- E4_NUTRIDEF
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E50-E64
- Name in latin
- Deficientia vitamini A
Similar endpoints
↥List of similar endpoints to
Vitamin A deficiency
based on the number of shared cases.
Similar with more cases:
- Vitamin deficiency
- Vitamin deficiency, wide
- Other nutritional deficiencies
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1746 | 1131 | 591 |
| Only index persons | 1302 | 892 | 410 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 65.53 | 63.81 | 68.82 |
| Only index persons | 58.80 | 56.29 | 64.25 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 163 | 107 | 56 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.03 |
| Median age at first event (years) | 52.41 | 43.74 | 68.97 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 170
- Matched controls
- 1700
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E50.9
ICD-10 Finland
Vitamin A deficiency, unspecified
+∞
98.9
85
*
E50.0
ICD-10 Finland
Vitamin A deficiency with conjunctival xerosis
+∞
36.8
34
*
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
9.3
30.8
43
60
H03BB01
ATC
carbimazole; oral
11.8
29.5
33
34
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
15.6
18.3
30
23
D64.9
ICD-10 Finland
Anaemia, unspecified
5.4
17.5
41
95
H03AA01
ATC
levothyroxine sodium; systemic
3.9
16.0
66
236
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
17.2
15.4
24
16
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
13.7
14.6
25
21
E50.7
ICD-10 Finland
Other ocular manifestations of vitamin A deficiency
+∞
13.7
13
*
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
4.1
12.0
39
116
E66.8
ICD-10 Finland
Other obesity
69.9
11.8
13
*
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
5.8
11.6
23
45
A10AB05
ATC
insulin aspart; parenteral
4.8
11.6
29
70
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.0
10.7
68
307
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
116.9
10.5
11
*
E66.01
ICD-10 Finland
Obesity due to excess calories
9.9
9.3
18
20
E66.00
ICD-10 Finland
Metabolic syndrome
15.1
8.9
14
10
I50.9
ICD-10 Finland
Heart failure, unspecified
3.0
8.4
44
176
E89.00
ICD-10 Finland
Postirradiation hypothyroidism
47.2
7.8
9
*
26000
ICD-8 Finland
Vitamin A deficiency, Night blindness
+∞
7.3
7
*
A10AE04
ATC
insulin glargine; parenteral
3.5
7.1
26
83
104
Kela drug reimbursment
Thyroid insufficiency
3.7
7.0
24
73
A10AC01
ATC
insulin (human); parenteral
3.5
6.9
26
84
SPAT1262
SPAT
Handing over of treatment supplies
2.9
6.8
36
143
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
6.8
73
411
R50.9
ICD-10 Finland
Fever, unspecified
2.9
6.7
36
145
103
Kela drug reimbursment
Diabetes, insulin-treated
2.5
6.6
54
269
UJF32
NOMESCO Finland
Coloscopy
2.4
6.4
54
272
E66.9
ICD-10 Finland
Obesity, unspecified
18.9
6.3
9
5
RD210, ,
NOMESCO Finland
18.9
6.3
9
5
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
6.2
6.3
16
28
E50.1
ICD-10 Finland
Vitamin A deficiency with Bitot spot and conjunctival xerosis
+∞
6.3
6
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
6.0
40
179
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
67
304
2.99
10.42
3.4
1.9
3.55
3.05
mg/l
0.91
62
262
39
168
2.71
6.35
2.2
2.0
14.92
20.84
%
2.22
33
144
90
569
2.24
6.20
20.6
13.7
1.29
1.24
inr
0.17
28
167
83
524
2.14
5.57
4.4
4.2
34.13
35.50
g/l
1.52
76
497
48
253
2.25
4.98
2.0
1.7
398.07
466.74
pmol/l
1.39
40
207
17
52
3.52
4.89
1.6
2.0
—
—
—
0
0
41
204
2.33
4.86
2.2
1.8
—
—
—
0
0
88
596
1.99
4.63
9.1
6.0
1.22
1.22
mmol/l
0.28
72
507
7
6
12.09
4.31
4.0
1.7
19.00
33.67
umol/l
—
7
6
43
232
2.14
4.15
2.0
1.7
1046.13
1174.76
nmol/l
0.38
35
175
100
725
1.92
4.14
9.3
9.2
4.76
4.10
e9/l
1.22
93
639
15
50
3.19
3.79
1.8
1.8
—
—
—
0
0
73
489
1.86
3.76
9.9
3.9
56.33
32.81
ng/l
0.65
50
327
22
93
2.57
3.66
2.0
1.5
—
—
—
0
0
80
556
1.83
3.63
7.5
5.0
1.22
1.22
mmol/l
0.38
69
511
91
661
1.81
3.55
6.8
5.6
9.96
10.43
umol/l
0.23
86
627
27
128
2.32
3.53
1.9
4.1
274.26
238.70
u/l
0.28
27
121
13
37
3.72
3.49
2.2
1.8
17.20
7.27
iu/l
—
6
14
13
40
3.43
3.22
1.5
1.1
—
—
—
0
0
71
502
1.71
2.88
2.2
1.9
115.64
92.96
pmol/l
2.27
44
261
119
968
1.76
2.88
7.9
3.9
15.61
14.67
pmol/l
3.14
106
864
71
509
1.68
2.70
3.0
2.3
73.13
76.70
nmol/l
0.62
65
451
20
94
2.28
2.67
1.9
3.1
60.75
76.33
ng/l
0.72
12
87
57
389
1.70
2.59
7.3
2.1
161.83
244.27
u/l
0.65
52
371
11
37
3.11
2.54
2.9
2.5
—
—
—
0
0
79
590
1.63
2.52
4.3
2.4
—
—
—
0
0
116
956
1.67
2.48
5.6
4.1
15.46
11.85
mm/h
1.66
108
871
20
98
2.18
2.43
19.5
2.4
4.68
8.68
ug/l
0.55
14
86
38
236
1.79
2.38
1.8
1.5
—
—
—
0
0
10
34
3.06
2.32
1.2
1.3
—
—
—
0
0
102
832
1.56
2.12
4.3
2.9
77.76
47.57
u/l
1.19
95
784
5
10
5.11
2.08
1.6
1.3
—
—
—
0
0
6
15
4.10
2.05
1.0
1.1
—
—
—
0
0
8
26
3.18
2.04
1.1
1.2
—
—
—
0
0
11
45
2.54
1.97
1.5
1.3
—
11.94
—
0
9
61
450
1.55
1.95
3.1
3.1
2.30
2.35
mmol/l
2.59
53
396
12
53
2.36
1.85
18.8
7.7
25.88
24.41
mmol/l
0.38
12
53
44
306
1.59
1.80
1.9
1.5
16.96
22.31
nmol/l
1.85
39
254
6
18
3.42
1.76
3.0
1.6
—
—
—
0
0
8
32
2.57
1.62
1.5
1.7
—
—
—
0
0
47
340
1.53
1.61
5.3
3.6
9.49
9.53
mg/mmol
0.00
33
222
40
281
1.55
1.56
2.1
1.8
1.03
1.28
mg/l
0.37
33
227
42
299
1.54
1.54
2.0
2.7
9298.44
7738.90
umol/l
0.06
36
253
7
27
2.66
1.53
2.1
2.7
3.57
3.91
g/l
—
7
27
6
21
2.92
1.52
1.3
1.2
—
—
—
0
0
9
38
2.44
1.48
1.3
1.4
—
—
—
0
0
9
38
2.44
1.48
1.1
1.1
—
—
—
0
0
41
294
1.52
1.45
4.2
2.1
—
—
—
0
0
13
67
2.02
1.42
1.8
1.7
—
—
—
0
0
6
23
2.67
1.38
1.5
1.3
—
—
—
0
0
5
17
3.00
1.37
1.0
1.0
—
—
—
0
0
6
24
2.55
1.31
4.7
3.8
61.17
60.58
%
—
6
24
5
117
0.41
1.31
1.2
1.7
—
—
—
0
0
16
260
0.58
1.29
1.2
1.5
—
—
—
0
0
131
1186
1.46
1.24
8.9
4.7
1.81
1.88
mu/l
0.24
120
1060
32
227
1.50
1.19
6.7
3.1
29.27
114.91
ng/l
1.43
24
173
25
171
1.54
1.10
1.6
2.2
—
—
—
0
0
9
46
2.01
1.05
1.0
2.2
—
—
—
0
0
12
69
1.80
0.99
1.8
1.3
—
—
—
0
0
20
135
1.55
0.94
2.8
1.7
—
—
—
0
0
6
28
2.18
0.92
1.0
1.3
—
—
—
0
0
20
136
1.53
0.91
2.8
1.7
—
—
—
0
0
9
53
1.74
0.77
8.3
3.3
53.88
49.02
%
—
9
53
5
26
1.95
0.71
1.0
1.3
—
—
—
0
0
137
1290
1.32
0.70
27.7
13.2
25.88
23.72
mg/l
0.20
116
1008
125
1164
1.28
0.69
7.5
5.2
43.74
39.59
mmol/mol
2.42
112
1078
8
50
1.63
0.62
1.6
1.5
—
—
—
0
0
6
39
1.56
0.53
2.2
1.9
—
—
—
0
0
7
45
1.58
0.49
1.0
1.2
—
—
—
0
0
7
46
1.54
0.49
14.1
1.7
—
—
—
0
0
7
46
1.54
0.49
1.0
1.2
—
—
—
0
0
39
331
1.23
0.49
1.4
1.2
0.51
1.21
u/ml
—
7
96
20
157
1.31
0.46
1.7
2.0
—
—
—
0
0
5
31
1.63
0.43
1.0
1.5
—
—
—
0
0
5
31
1.63
0.43
1.0
1.3
—
—
—
0
0
8
57
1.42
0.43
6.1
2.1
1.04
1.19
%
—
8
57
13
98
1.35
0.38
20.4
5.1
1.57
1.37
mmol/l
0.25
13
98
51
457
1.17
0.36
5.1
3.0
—
—
—
0
0
6
42
1.44
0.36
1.2
1.6
—
—
—
0
0
56
509
1.15
0.33
7.0
3.8
—
—
—
0
0
135
1303
1.18
0.33
32.1
14.7
139.14
139.66
mmol/l
1.55
130
1254
11
84
1.33
0.31
1.3
1.3
34.73
159.21
u/ml
4.01
11
73
135
1306
1.16
0.30
32.3
14.8
3.97
3.95
mmol/l
0.36
130
1256
12
95
1.28
0.27
1.3
1.2
146.20
115.35
iu/ml
—
5
45
5
75
0.66
0.26
1.2
1.0
—
—
—
0
0
122
1261
0.88
0.26
5.5
4.7
2.45
2.72
mmol/l
2.53
112
1151
119
1231
0.89
0.25
5.5
4.4
6.06
5.84
mmol/l
0.75
108
1113
9
77
1.18
0.25
1.0
1.4
—
—
—
0
0
5
38
1.33
0.23
2.0
2.7
—
—
—
0
0
15
126
1.21
0.22
5.8
3.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
7.01
—
0
11
0
10
0.00
0.21
0.0
1.5
—
9.47
—
0
10
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
15
172
0.86
0.16
3.1
2.9
0.81
0.95
ug/l
—
9
123
117
1200
0.92
0.16
23.6
12.5
81.34
81.54
ml/min/173m2
0.03
105
959
7
86
0.81
0.15
1.0
1.6
—
—
—
0
0
68
653
1.07
0.13
6.3
3.7
0.00
0.00
estimate
-0.00
13
118
18
199
0.89
0.12
2.6
2.8
4.60
2.75
e6/l
—
8
110
120
1224
0.93
0.12
5.1
4.2
1.43
1.52
mmol/l
1.17
108
1120
139
1369
1.08
0.11
13.9
9.8
24.26
24.35
u/l
0.03
133
1310
86
835
1.06
0.11
3.4
3.3
—
—
—
0
0
5
48
1.04
0.09
1.2
1.4
—
—
—
0
0
7
83
0.84
0.07
2.4
1.9
—
—
—
0
0
24
229
1.06
0.04
4.5
4.2
24.41
21.08
%
0.76
12
124
24
229
1.06
0.04
1.2
1.3
1.47
10.97
u/ml
—
6
97
35
362
0.96
0.04
7.7
4.0
0.00
0.00
estimate
-0.00
14
121
66
647
1.03
0.04
8.8
5.0
0.00
0.00
estimate
-0.00
14
123
66
647
1.03
0.04
6.5
3.7
0.00
0.01
estimate
0.50
14
129
11
101
1.10
0.04
2.1
2.0
—
—
—
0
0
14
149
0.93
0.03
9.4
7.1
—
—
—
0
0
136
1351
1.03
0.02
30.3
15.0
77.30
74.58
umol/l
0.50
136
1351
122
1229
0.97
0.02
5.1
4.2
4.37
4.66
mmol/l
2.03
111
1135
119
1181
1.03
0.02
4.5
3.8
1.41
1.21
mmol/l
1.11
108
1072
144
1437
1.01
0.00
39.1
19.3
38.86
39.73
%
0.83
133
1356
36
363
0.99
0.00
5.3
2.9
0.09
0.33
e6/l
2.21
27
259
21
212
0.99
0.00
3.1
2.6
0.90
1.05
e6/l
0.19
12
121
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
9.24
—
0
6
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
3.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
47.50
—
0
6
0
6
0.00
0.00
0.0
4.7
—
146.50
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
3.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
5
49
1.02
0.00
1.0
1.1
—
11.60
—
0
9
0
8
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1883.67
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
90.60
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
7
73
0.96
-0.00
38.0
4.4
24.36
24.50
mmol/l
—
7
73
Mortality – FinRegistry
↥Association
Association between endpoint E4_VIT_A_DEF and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_VIT_A_DEF | 2.193 [1.78, 2.7] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.182 |
During the follow-up period (1.1.1998 — 31.12.2019), 420 out of 942 females with E4_VIT_A_DEF died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_VIT_A_DEF | 2.936 [2.06, 4.18] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 282 out of 450 males with E4_VIT_A_DEF died.
Mortality risk
Mortality risk for people of age
years, who have E4_VIT_A_DEF.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.208% | 0.662% |
| 5 | 1.253% | 3.621% |
| 10 | 2.98% | 7.887% |
| 15 | 5.729% | 14.718% |
| 20 | 10.213% | 23.711% |
Relationships between endpoints
↥Index endpoint: E4_VIT_A_DEF – Vitamin A deficiency
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data